Back to discover
Disease

Proteinuria

Late-stage therapeutic developmentEmerging research
MeSHProteinuria
2
Publications
19
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q1 2027.
Upcoming Milestones
Clinical Milestones7View
Results expected 4
Recently completed 3
Activity timeline7

Clinical trials

16 sponsors · 2 new · 1 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
19
All trials
6
Active
17
Late-stage
6
Completed
Late-stage studies

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Phase 3 · Recruiting · Bayer

An Study on the Efficacy and Safety of Finerenone in Proteinuria Patients After Kidney Transplantation

Phase 3 · Active, not recruiting · kewen Chen,MD

A Multicenter, Open-label Single Arm Study to Evaluate the Safety and Efficacy of Sparsentan in Posttransplant Immunoglobulin A Nephropathy (IgAN) or Focal Segmental Glomerulosclerosis (FSGS) (SPARX)

Phase 4 · Active, not recruiting · Travere Therapeutics, Inc.

A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria

Phase 3 · Recruiting · Bayer

Comparative Analysis of ARBs Alone or in Combination of SGLT2i in Management of Proteinuria in Normotensive Diabetic Patients

Phase 2/3 · Active, not recruiting · Dr Mudassar Saeed Pansota

Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.

Phase 4 · Completed · University Medical Center Groningen
Recruiting

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Phase 3 · Recruiting · Bayer

A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria

Phase 3 · Recruiting · Bayer

An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria

Phase 2 · Recruiting · SynAct Pharma Aps
Recently completed

Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.

Phase 4 · Completed · University Medical Center Groningen

Efficacy and Safety of Dapagliflozin in Non-diabetic Children With Proteinuria

Phase 4 · Completed · Children's Hospital of Fudan University

Effect of Sodium Glucose Transporter 2 Inhibitor Empagliflozin on Proteinuria and Kidney Disease Progression in Patients With Non-diabetic Glomerulonephritis- A Randomized Controlled Trial

Phase 3 · Completed · Kasr El Aini Hospital

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects With Persistent Proteinuria and Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy (iMN)

Phase 4 · Completed · Mallinckrodt

Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria

Phase 4 · Completed · Assistance Publique - Hôpitaux de Paris

Efficacy and Safety of Selective Vitamin D Receptor Activation With Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients: a Randomized Controlled Trial

Phase 3 · Completed · University Medical Centre Ljubljana

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20202023
Major themes3
  • Lupus Erythematosus, Systemic1
  • Lupus Nephritis1
  • Podocytes1
Leading journals2
  • Molecular medicine reports1
  • Pediatric nephrology (Berlin, Germany)1
Leading researchers8
  • Anochie I1
  • Becker JU1
  • Boyer O1
  • Cano F1
  • Feltran L1
  • Gipson D1
  • Haffner D1
  • Hodson E1
Affiliations (unnormalised)6
  • Alberta Children's Hospital1
  • All India Institute of Medical Sciences1
  • Bambino Gesù Pediatric Hospital and Research Center1
  • Basic Medical College1
  • Bristol Royal Hospital for Children1
  • Center for Pediatrics and Adolescent Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

The presence of proteins in the urine, an indicator of KIDNEY DISEASES.

Identifiers
MeSHProteinuria
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.